2. Search Result
Search Result
Results for "

CDK2-IN-50

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1465
    Aristolochic acid D

    Aristolochic acid-IVa

    		 Phosphodiesterase (PDE) CDK Interleukin Related Inflammation/Immunology Cancer
    Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC50: 4.673 μM) and CDK2 (IC50: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .
    Aristolochic acid D
  • HY-103712
    Samuraciclib
    Maximum Cited Publications
    10 Publications Verification

    CT7001; ICEC0942

    		 CDK Apoptosis Cancer
    Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .
    Samuraciclib
  • HY-103712A
    Samuraciclib hydrochloride
    Maximum Cited Publications
    10 Publications Verification

    CT7001 hydrochloride; ICEC0942 hydrochloride

    		 CDK Apoptosis Cancer
    Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .
    Samuraciclib hydrochloride
  • HY-103712C
    Samuraciclib hydrochloride hydrate
    Maximum Cited Publications
    10 Publications Verification

    CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate

    		 CDK Apoptosis Cancer
    Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
    Samuraciclib hydrochloride hydrate
  • HY-124760
    hSMG-1 inhibitor 11e
    3 Publications Verification

    		 mTOR PI3K CDK Cancer
    hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM) .
    hSMG-1 inhibitor 11e
  • HY-103712B
    Samuraciclib hydrochloride dihydrate
    Maximum Cited Publications
    10 Publications Verification

    CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate

    		 CDK Apoptosis Cancer
    Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
    Samuraciclib hydrochloride dihydrate
  • HY-179231
    CDK2-IN-50

    		CDK Apoptosis Cancer
    CDK2-IN-50 is a CDK2 inhibitor (IC50 = 0.77 nM). CDK2-IN-50 can induce G1 phase arrest, indicating that it has an effective CDK2/cyclin E targeting mechanism. CDK2-IN-50 also has a significant pro-apoptotic effect. CDK2-IN-50 can be used for the study of breast cancer .
    CDK2-IN-50
  • HY-173224
    CDK2/PIM1-IN-1

    		CDK Pim Cancer
    CDK2/PIM1-IN-1 is an inhibitor of CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity .
    CDK2/PIM1-IN-1
  • HY-N1465R
    Aristolochic acid D (Standard)

    Aristolochic acid-IVa (Standard)

    		 Reference Standards CDK Phosphodiesterase (PDE) Interleukin Related Inflammation/Immunology Cancer
    Aristolochic acid D (Standard) (Aristolochic acid-IVa (Standard)) is the analytical standard of Aristolochic acid D (HY-N1465). This product is intended for research and analytical applications. Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC50: 4.673 μM) and CDK2 (IC50: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .
    Aristolochic acid D (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: